logo

Last Update

This profile was last updated on 8/19/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong John Manthei?

John R. Manthei

Partner

Latham & Watkins LLP

HQ Phone:  (212) 906-1200

Direct Phone: (202) ***-****direct phone

Email: j***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Latham & Watkins LLP

885 Third Avenue

New York City, New York,10022

United States

Company Description

Latham & Watkins LLP operates worldwide as a limited liability partnership organized under the laws of the State of Delaware (USA) with affiliated limited liability partnerships conducting the practice in the United Kingdom, France, Italy and Singapore and as ...more

Web References(91 Total References)


Key Regulatory Issues in Biosimilars - Food and Drug Law Institute (FDLI)

www.fdli.org [cached]

JOHN MANTHEI is a partner at Latham and Watkins and global co-chair of the Healthcare and Life Sciences Practice, where he specializes in regulatory matters involving the US Food and Drug Administration (FDA) for the medical device, pharmaceutical, and biotechnology industries.
He advises clients on all aspects of the FDA-regulated product life cycle, post market enforcement, and administrative litigation. Mr. Manthei currently serves as outside FDA counsel to the Medical Device Manufacturers Association (MDMA), a member of the Food & Drug Law Institute (FDLI) Advisory Committee for Medical Devices, and a former member of the FDLI Advisory Committee for Drugs and Biologics. He previously served as Majority Counsel for the US House of Representatives' Committee on Energy and Commerce (1998-2000). Mr. Manthei is recognized as a leading FDA attorney in industry publications such as Chambers USA (2010-2016) and The Legal 500 US (2012-2016). He has also been named a "Life Sciences Star" by Euromoney (2012-2016) and a "Top 40 Lawyers Under 40" by Washingtonian magazine (2006).


Committees - Food and Drug Law Institute (FDLI)

www.fdli.org [cached]

John R. Manthei (Committee Member) Latham & Watkins LLP


Board of Directors | Neediest Kids

neediestkids.org [cached]

John Manthei, Esq., Latham & Watkins


Latham & Watkins LLP - About Us - News - Medicis Pharmaceutical Advised in its $2.6 Billion Acquisition by Valeant

www.latham.com [cached]

Advice was also provided on antitrust matters by partner Michael Egge with associate Jason Cruise in Washington D.C.: on benefits and compensation matters by partner Jim Barrall in Los Angeles with associate Carol Samaan in Orange County; on litigation matters by partners David Schindler in Los Angeles and Michele Johnson in Orange County; on regulatory matters by partner John Manthei with associate Elizabeth Richards in Washington D.C.; on intellectual property matters by partner Judith Hasko in Silicon Valley; on environmental matters by partner Christopher Norton in Orange County; and on tax matters by partner Nicholas DeNovio in Washington D.C.
John R. Manthei


www.odtmag.com

John Manthei, a partner at global law firm Latham & Watkins LLC called Sharfstein's resignation a key loss for the FDA and said agency officials must decide on the kind of role they want his replacement to undertake.
"Josh has been very active and he's been a key player at the FDA for the last few years," Manthei told Orthopedic Design & Technology.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory